Sub-penny stocks, often overlooked, hold unique advantages for investors seeking high-reward opportunities. These low-cost stocks offer not only affordability but also the potential for explosive gains.
Through diligent research, it is often possible to find verifiable gems. Let’s take a closer look at four sub-penny stocks that are gaining momentum in their sectors.
Epazz Inc. (OTC: EPAZ): The global drone market is experiencing significant changes while growing at a compound annual rate of over 30%. With the market expected to be worth over $190 billion by 2028, up from about $30 billion as of 2022, numerous opportunities are increasingly cropping up. Epazz is one of the companies that has positioned itself to take advantage of the tremendous opportunities up for grabs.
The mission-critical provider of drone technologies has been making waves in the burgeoning segment with its proprietary ZenaDrone 1000 technology. The company has affirmed its commitment to improving intelligent, unmanned aerial vehicle technology and incorporating machine learning software and artificial intelligence.
Consequently, its game-changing ZenaDrone 1000 continues to elicit strong interest from various sectors, from agriculture to industrial and military operations. Likewise, the company has started deploying drones for drone service operations.
Amid the strong interest, Epazz confirmed the completion of a successful presentation with several government security agencies in the US on August 31, 2023. Similarly, the company is working on signing several agencies as pilot customers for its ZenaDrone 1000. The company plans to make the drones available to government security agencies for up to 90 days for initial testing and feedback.
Shaun Passley, Ph.D., CEO of Epazz Inc., said, “We are excited about the next nine months; our marketing efforts are working, and we are turning meetings into demos, and finally we are getting close to the next level.”
In addition, Epazz has confirmed plans to continue signing up military and government agencies in the third quarter. It also plans to increase production of the game-changing ZenaDrone 1000 to meet the growing demand. On August 24, it confirmed a joint venture in Brazil to establish a facility and infrastructure for ZenaDrone 1000 operations.
Epazz continues to experience strong demand, with ZenaDrone 1000 having already captured the interest of over 25 esteemed Brazilian organizations. The strong demand has already forced the company to add a Portuguese-language option to its website to ensure seamless communication and accessibility. The focus now shifts to completing the joint venture in Brazil in the third quarter and beginning the process of starting another joint venture in South Africa and India as part of the international expansion drive.
The expansion drive affirms that Epazz is on track to generate revenue from drone service operations before year-end. The company has been working on unlocking revenue opportunities around its ZenaDrone 1000 technology to supplement its cloud-based software solutions. On August 16, the company reported revenues of $580,530 for its second quarter, up from $511,633 last year. The revenues were mainly generated by the company’s cloud business software products.
Even as software products account for the biggest share of the company’s revenues, Epazz remains focused on unlocking value in its ZenaDrone technology. The company has also been upgrading its technology with artificial intelligence engines to strengthen its competitive edge in the industry.
Transportation and Logistics Systems Inc. (OTC:TLSS): The company, which operates through a number of subsidiaries, is engaged in providing logistics and transportation services in the North American market. It also provides last-mile delivery, long-haul and mid-mile services, last-mile delivery, and two-person deliveries. Additionally, Transportation and Logistics Systems Inc. also provides warehousing and pickup services.
On September 6, Transportation and Logistics Systems announced that it had started providing delivery services in the entirety of its coverage area as a company. It would provide the services through a partnership with the expedited LTL carrier based out of Fontana, California, named Expediri Inc.
The Chief Executive Officer and Chairman of the Company, Sebastian Giordano, spoke about the latest major move from the company. He asserted that the company already enjoyed a significant reputation and presence in the Northeastern region.
Hence, the management had made continuous efforts to get hold of new business to boost revenues. Giordano stated that everyone at the company was excited about the new agreement with Expediri, which enjoys a strong presence on the West Coast. He also commended the sales and commerce teams at Transportation and Logistics Systems for their focus as well as their hard work in aggressively pursuing organic growth.
The Vice President of Operations at Expediri, Jason Coronado, provided his insights about the deal as well. He noted that, in its capacity as a niche LTL player, it offered its clients concierge-level services.
The average length of a haul from the company stood at 2900 miles, and there were a number of factors that went into providing the service. Coronado stated that in order to sell its services, it needed a partner who was on the same wavelength, and on that measure, Transportation and Logistics Systems proved to be the best fit.
Enzolytics Inc. (OTC:ENZC): The company is involved in drug development and committed to commercializing its monoclonal antibodies as well as proprietary proteins, which are meant for treating impairing infectious diseases.
On September 6, the company’s fully owned subsidiary unit, Virogenetics Inc., made a key announcement. It revealed that, based on the Bulgarian population of individuals infected with HIV, the sample size for the ITV-1 clinical trials had been set at 60. The trials would be managed by R&D Services, Ltd. Aneliya Vidinlieva, the manager of clinical trials at R&D Services, would be in charge of the trials. She would be assisted by three consultants who would be assigned by the University of Pharmacology and the Chief Medical Officer of Desing, Dr. Ivaylo Tsonev.
“With the quality of our partners and our past success with ITV-1 clinical trials, we at VIRO are expecting great success in not only the ITV-1 application to HIV but also its application to diabetes and other areas being pursued,” stated Harry Zhabilov, CSO of VIRO.
The clinical trial would be conducted in places spread across Bulgaria. R&D Services would manage the administration of the ITV-1 clinical trials, which would be conducted in public, private, and municipal healthcare organizations. In the news release, Virogenetics also noted that on top of the clinical trials that would be managed by R&D Services, a review by an immunologist would also be included. The review would help in the evaluation of any correlation in patient outcomes with different origins of immune deficiency.
The therapeutic developments from Virogenetics would also entail participation from a number of well-known pharmaceutical entities. One of those would be VETPROM AD, a business division of the French firm Danhson.
Danhson boasts of having operated in Bulgaria continuously for more than 65 years, and currently, it is one of the biggest pharmaceutical, medicinal, cosmetic, and food supplement manufacturers in the country. The CSO of Virogenetics, Harry Zhabilov, noted that due to the expertise of its partners, the team at the company anticipated ‘great success’ in the clinical trials and also in other endeavors.
Hannover House Inc. (OTC:HHSE): The company is a worldwide media production and distribution entity. Hannover House Inc. is involved in the production and distribution of video and feature films to video, television networks, digital streaming platforms, and international licensors. It is also involved in the publication of both nonfiction and fiction books.
On September 1, the company announced that it had been successful in reducing its debt load significantly to $2.7 million from $6.4 million. It was a significant announcement considering that Hannover House had also been making preparations for the launch of MyFlix. The financial leeway would help the company produce high-quality films.
The company revealed that the debt reductions had taken place not only through payments but also through negotiated reductions. Hannover House incurred considerable debts, through ‘default judgments’, in the period from 2016 to 2018, due to a faulty legal strategy that had been deployed by the company’s management.
The legal actions that had been filed out of state had been ignored and allowed to go into default since the management believed that disputes had to be filed in Arkansas. Eric Parkinson, the Chief Executive Officer of the company, noted that due to the collapse in demand for DVDs, some of the company’s suppliers fled lawsuits for DVDs that had been returned unsold.
He went on to add that the lawsuits lacked any merit, but they loaded Hannover House with debts. However, he noted that the issue had been resolved and thanked the judgment holders as well as the company’s creditors.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer.